14th C1-Inhibitor Deficiency and Angioedema Workshop

May 29 - Jun 1, 2025

  • Title: Clinical Validation of a Novel Biomarker Assay to Characterize Bradykinin-Mediated Angioedema in Prospective and Biobank Plasma Samples
    Presenter: Evangelia Pardali, Ph.D.
    Format: Oral Presentation, O-02
    Date, Time: Friday, May 30, 8:45-9:00 CEST (2:45-3:00 a.m. ET)
  • Title: Long-Term Prophylactic Treatment With Oral Deucrictibant Improves Health-Related Quality of Life and Disease Control in Participants With Hereditary Angioedema: CHAPTER-1 Open-Label Extension Study
    Presenter: Markus Magerl, M.D.
    Format: Poster Presentation, P-19
    Date, Time: Friday, May 30, 15:45-17:30 CEST (9:45-11:30 a.m. ET)
  • Title: Sustained Therapeutic Exposure with Once-Daily Oral Deucrictibant XR Tablet for Prophylaxis of Hereditary Angioedema Attacks: Results of a Pharmacokinetics Study in Healthy Volunteers
    Presenter: Zhi-Yi Zhang, Ph.D. 
    Format: Poster Presentation, P-20
    Date, Time: Friday, May 30, 15:45-17:30 CEST (9:45-11:30 a.m. ET)
  • Title: Acquired Angioedema Due to C1-Inhibitor Deficiency: Patient Experience and Assessment of Patient-Reported Outcome Measures
    Presenter: Andrea Zanichelli, M.D., Ph.D.
    Format: Poster Presentation, P-17
    Date, Time: Friday, May 30, 15:45-17:30 CEST (9:45-11:30 a.m. ET)
  • Title: Long-Term Safety and Efficacy of Oral Deucrictibant for Prophylaxis in Hereditary Angioedema: Data Snapshot Results of the CHAPTER-1 Open-Label Extension Study
    Presenter: Emel Aygören-Pürsün, M.D.
    Format: Oral Presentation, O-33
    Date, Time: Saturday, May 31, 15:30-15:45 (9:30-9:45 a.m. ET)
  • Title: Long-Term Safety and Efficacy of Oral Deucrictibant for Treatment of Hereditary Angioedema Attacks: Results of the RAPIDe-2 Extension Study
    Presenter: Marc A. Riedl, M.D., M.S.
    Format: Oral Presentation, O-02
    Date, Time: Friday, May 30, 8:45-9:00 CEST (2:45-3:00 a.m. ET)
  • Title: Durability Of Response to a Single Dose of Oral Deucrictibant for On-Demand Treatment of Hereditary Angioedema Attacks
    Presenter: Anna Valerieva, M.D., Ph.D.
    Format: Poster Presentation, P-56
    Date, Time: Saturday, May 31, 16:45-17:45 CEST (10:45-11:45 a.m. ET)
  • Title: CHAPTER-3 Phase 3 Trial Design: Efficacy and Safety of the Oral Bradykinin B2 Receptor Antagonist Deucrictibant Extended-Release Tablet for Prophylaxis of Hereditary Angioedema Attacks
    Presenter: Andrea Zanichelli, M.D., Ph.D.
    Format: Poster Presentation, P-42
    Date, Time: Saturday, May 31, 16:45-17:45 CEST (10:45-11:45 a.m. ET)
  • Title: Safety and Efficacy of Oral Deucrictibant for Treatment of Upper Airway and Laryngeal Hereditary Angioedema Attacks: Results from the RAPIDe-2 Extension Study
    Presenter: Ramón Lleonart, M.D.
    Format: Poster Presentation, P-55
    Date, Time: Saturday, May 31, 16:15-17:45 CEST (10:15-11:45 a.m. ET)
  • Title: Epidemiology of Bradykinin-Mediated Angioedema in the European Population
    Presenter: Emel Aygören-Pürsün, M.D.
    Format: Poster Presentation, P-30
    Date, Time: Saturday, May 31, 16:15-17:45 CEST (10:15-11:45 a.m. ET)

Supporting Materials

Clinical Validation of a Novel Biomarker Assay to Characterize Bradykinin-Mediated Angioedema in Prospective and Biobank Plasma Samples 622.3 KB
Long-Term Prophylactic Treatment With Oral Deucrictibant Improves Health-Related Quality of Life and Disease Control in Participants With Hereditary Angioedema: CHAPTER-1 Open-Label Extension Study 509.5 KB
Sustained Therapeutic Exposure with Once-Daily Oral Deucrictibant XR Tablet for Prophylaxis of Hereditary Angioedema Attacks: Results of a Pharmacokinetics Study in Healthy Volunteers 671.2 KB
Acquired Angioedema Due to C1-Inhibitor Deficiency: Patient Experience and Assessment of Patient-Reported Outcome Measures 368.7 KB
Durability Of Response to a Single Dose of Oral Deucrictibant for On-Demand Treatment of Hereditary Angioedema Attacks 360.7 KB
CHAPTER-3 Phase 3 Trial Design: Efficacy and Safety of the Oral Bradykinin B2 Receptor Antagonist Deucrictibant Extended-Release Tablet for Prophylaxis of Hereditary Angioedema Attacks 1 MB
Safety and Efficacy of Oral Deucrictibant for Treatment of Upper Airway and Laryngeal Hereditary Angioedema Attacks: Results from the RAPIDe-2 Extension Study 387 KB
Epidemiology of Bradykinin-Mediated Angioedema in the European Population 991.1 KB
Long-Term Safety and Efficacy of Oral Deucrictibant for Prophylaxis in Hereditary Angioedema: Data Snapshot Results of the CHAPTER-1 Open-Label Extension Study 529.5 KB
Long-Term Safety and Efficacy of Oral Deucrictibant for Treatment of Hereditary Angioedema Attacks: Results of the RAPIDe-2 Extension Study 411.8 KB